Aytu BioPharma Inc. (AYTU)
AYTU trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1385818/000143774926030908/0001437749-26-030908-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | AYTU on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001385818 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $57.6M |
| Net income | -$14.3M |
| Operating income | -$8.3M |
| Net margin | -24.8% |
| Operating margin | -14.4% |
| Revenue growth | -13.3% |
| Cash | $26.3M |
| Total assets | $105.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-K 2026-09-22 |
| Cash and burn | $26.3M cash; operating cash flow $820K a quarter. | Report 2026-06-30 |
| Shares outstanding | 10,866,708 (2026-09-15); 9,911,913 a year earlier; 5,530,027 three years earlier. | Cover page 2026-09-15 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton LLP, Denver, Colorado, United States | PCAOB Form AP 2026-10-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q4 2026 2026-06-30 | $16.1M | -$15K | $4.4M | $26.3M | $11.0M | $57.6M | 10-K 2026-09-22 |
| Q3 2026 2026-03-31 | $12.4M | -$5.6M | -$4.2M | $26.7M | $11.4M | $56.6M | 10-Q 2026-05-13 |
| Q2 2026 2025-12-31 | $15.2M | -$10.6M | $3.7M | $30.0M | $11.9M | $62.6M | 10-Q 2026-02-03 |
| Q1 2026 2025-09-30 | $13.9M | $2.0M | -$618K | $32.6M | $12.3M | $63.7M | 10-Q 2025-11-13 |
| Q4 2025 2025-06-30 | $15.1M | -$19.8M | $2.8M | $31.0M | $12.8M | $66.4M | 10-K 2026-09-22 |
| Q3 2025 2025-03-31 | $18.5M | $4.0M | -$6.5M | $18.2M | $11.4M | $65.8M | 10-Q 2026-05-13 |
| Q2 2025 2024-12-31 | $16.2M | $788K | $2.9M | $20.4M | $15.9M | $61.4M | 10-Q 2026-02-03 |
| Q1 2025 2024-09-30 | $16.6M | $1.5M | -$1.2M | $20.1M | $16.6M | $63.9M | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B4 | 424B4 | 2025-06-09 |
| Latest annual report FORM 10-K | 10-K | 2026-09-22 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-05-13 |
| Latest current report FORM 8-K | 8-K | 2026-11-16 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-10-27 |
Source: SEC EDGAR submissions feed, 910 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.7% |
| 1 month | -10.6% |
| 3 months | -22.6% |
| Year to date | -31.5% |
| 1 year | -13.6% |
| From 52-week high | -38.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CELU | Celularity Inc. | $0.6191 | -1.75% | $20.1M |
| SHPH | Shuttle Pharmaceuticals Holdings Inc. | $4.24 | -6.40% | $20.2M |
| ATOS | Atossa Therapeutics Inc. | $1.93 | -1.53% | $19.3M |
| IGC | IGC Pharma Inc. | $0.1750 | -0.57% | $20.4M |
| CPHI | China Pharma Holdings Inc. | $0.4800 | -7.35% | $20.7M |
| COCP | Cocrystal Pharma Inc. | $0.9777 | -0.24% | $18.8M |
| TXMD | TherapeuticsMD Inc. | $1.81 | -3.21% | $20.9M |
| LPCN | Lipocine Inc. | $1.66 | -2.92% | $18.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier